Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein

International Journal of Cancer

Volumn 72, Issue 4, 1997, Pages 614-618

  Bryden, Helen ^b   Mackenzie, Jane ^a   Andrew, Linda ^a   Alexander, Freda E ^b   Angus, Brian ^c   Krajewski, Andrew S ^a   Armstrong, Alison A ^a   Gray, Diane ^a   Cartwright, Ray A ^b   Kane, Eleanor ^d   Wright, Denis H ^e   Taylor, Penny ^c   Jarrett, Ruth F ^a,f  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HLA SYSTEM; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; VIRUS CARCINOGENESIS; ADOLESCENT; ADULT; ALLELE; GENETICS; HERPES VIRUS INFECTION; IMMUNOLOGY; MUTATION; VIROLOGY; VIRUS INFECTION;

EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPITOPE; HLA A ANTIGEN; MATRIX PROTEIN; ONCOPROTEIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ALLELES; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HLA-A ANTIGENS; HODGKIN DISEASE; HUMANS; IMMUNODOMINANT EPITOPES; MUTATION; ONCOGENE PROTEINS, VIRAL; TUMOR VIRUS INFECTIONS; VIRAL MATRIX PROTEINS;

EID: 0030611238     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970807)72:4<614::AID-IJC11>3.0.CO;2-B     Document Type: Article

References (26)

1. ARMSTRONG, A.A., WEISS, L.M., GALLAGHER, A., JONES, D.B., KRAJEWSKI, A.S., ANGUS, B., BROWN, G., JACK, A.S., WILKINS, B.S., ONIONS, D.E. and JARRETT, R.F., Criteria for the definition of Epstein-Barr virus association in Hodgkin's disease. Leukemia, 6, 869-874 (1992).
2. + population. Science, 260, 98-100 (1993).
3. DE CAMPOS-LIMA, P.O., LEVITSKY, V., BROOKS, J., LEE, S.P., HU, L.F., RICKINSON, A.B. and MASUCCI, M.G., T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J. exp. Med., 179, 1297-1305 (1994).
4. DEACON, E.M., PALLESEN, G., NIEDOBITEK, G., CROCKER, J., BROOKS, L., RICKINSON, A.B. and YOUNG, L.S., Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. exp. Med., 177, 339-349 (1993).
5. FRISAN, T. and 15 OTHERS. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood, 86, 1493-1501 (1995).
6. GLEDHILL, S., GALLAGHER, A., JONES, D.B., KRAJEWSKI, A.S., ALEXANDER, F.E., KLEE, E., WRIGHT, D.H., O'BRIEN, C., ONIONS, D.E. and JARRETT, R.F., Viral involvement in Hodgkin's disease: detection of clonal type A Epstein-Barr viral genomes in tumour samples. Brit. J. Cancer. 64, 227-232 (1991).
7. GRASSER, F.A., MURRAY, P.G., KREMMER, E., KLEIN, K., REMBERGER, K., FEIDEN, W., REYNOLDS, G., NIEDOBITEK, G., YOUNG, L.S. and MUELLER-LANTZSCH, N., Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood, 84, 3792-3798 (1994).
8. HIGUCHI, R., Simple and rapid preparation of samples for PCR. In: H.A. Erlich (ed.), PCR technology. Principles and applications for DNA amplification, pp. 31-38, Stockton Press, New York (1989).
9. IMANISHI, T., AKAZA, T., KIMURA, A., TOKUNAGA, K. and GOJOBORI, T., Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: K. Tsuji, M. Aizawa and T. Sasazuki (eds.), HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference, pp. 1065-7474, Oxford University Press, Oxford (1992).
10. JARRETT, R.F., GALLAGHER, A., JONES, D.B., ALEXANDER, F.E., KRAJEWSKI, A.S., KELSEY, A., ADAMS, J., ANGUS, B., GLEDHILL, S., WRIGHT, D.H., CARTWRIGHT, R.A. and ONIONS, D.E., Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. J. clin. Pathol., 44, 844-848 (1991).
11. KHANNA, R., BURROWS, S.R., KURILLA, M.G., JACOB, C.A., MISKO, I.S., SCULLEY, T.B., KIEFF, E. and MOSS, D.J., Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. exp. Med., 176, 169-176 (1992).
12. KRAUSA, P. and 13 OTHERS, Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens, 45, 223-231 (1995).
13. KRAUSA, P., MOSES, J., BOOMER, W., BOOMER, J. and BROWNING, M., HLA-A locus alleles identified by sequence specific PCR (21). Lancet, 341, 121-122 (1993).
14. LEE, S.P., THOMAS, W.A., MURRAY, R.J., KHANIM, F., KAUR, S., YOUNG, L.S., ROWE, M., KURILLA, M. and RICKINSON, A.B., HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J. Virol., 67, 7428-7435 (1993).
15. LONGNECKER, R. and KIEFF, E., A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J. Virol., 64, 2319-2326 (1990).
16. MURRAY, R.J., KURILLA, M.G., BROOKS, J.M., THOMAS, W.A., ROWE, M., KIEFF, E. and RICKINSON, A.B., Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. exp. Med., 176, 157-168 (1992).
17. OUDEJANS, J.J., JIWA, N.M., KUMMER, J.A., HORSTMAN, A., VOS, W., BAAK, J.P., KLUIN, P.M., VAN DER VALK, P., WALBOOMERS, J.M. and MEIJER, C.J., Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood, 87, 3844-3851 (1996).
18. PALLESEN, G., HAMILTON-DUTOIT, S.J., ROWE, M. and YOUNG, L.S., Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet, 337, 320-322 (1991).
19. PARHAM, P. and BRODSKY, P.M., Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol., 3, 277-299 (1981).
20. PHILLIPS, R.E., ROWLAND JONES, S., NIXON, D.F., GOTCH, F.M., EDWARDS, J.P., OGUNLESI, A.O., ELVIN, J.G., ROTHBARD, J.A., BANGHAM, C.R.M., RIZZA, C.R. and MCMICHAEL, A.J., Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (Lond.), 354, 453-459 (1991).
21. POPPEMA, S. and VISSER, L., Epstein-Barr virus positivity in Hodgkin's disease does not correlate with an HLA A2-negative phenotype. Cancer, 73, 3059-3063 (1994a).
22. POPPEMA, S. and VISSER, E., Absence of HLA class I expression by Reed-Sternberg cells. Amer. J. Pathol., 145, 37-41 (1994b).
23. SAMPLE, J., LIEBOWITZ, D. and KIEFF, E., Two related EBV membrane proteins are encoded by separate genes. J. Virol., 63, 933-937 (1989).
24. SHIMIZU, H. and BURNS, J.C., Extraction of nucleic acids: sample preparation from paraffin-embedded tissues. In: M.A. Innis, D.H. Gelfand and J.J. Sninsky (eds.), PCR strategies, pp. 32-38, Academic Press, London (1995).
25. TRAINOR, C.D., WONG STAAL, F. and REITZ, M.S., Comparative restriction endonuclease maps of proviral DNA of the primate type C simian sarcoma-associated virus and gibbon ape leukemia virus group. J. Virol., 41, 298-308 (1982).
26. WEISS, L.M., STRICKLER, J.G., WARNKE, R.A., PURTILO, D.T. and SKLAR, J., Epstein-Barr viral DNA in tissues of Hodgkin's disease. Amer. J. Pathol., 129, 86-91 (1987).